Sonia Guadalupe Barreno-Rocha

Ms. Sonia Guadalupe Barreno-Rocha

Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SBSonia Guadalupe Barreno-Rocha
Sonia Guadalupe Barreno-Rocha
SGSandra Guzmán-Silahua
Sandra Guzmán-Silahua
SRSinaí-Del-Carmen Rodríguez-Dávila
Sinaí-Del-Carmen Rodríguez-Dávila
GGGuadalupe Estela Gavilánez-Chávez
Guadalupe Estela Gavilánez-Chávez
EMErnesto Germán Cardona Muñoz
Ernesto Germán Cardona Muñoz
ANArnulfo Hernan Nava-Zavala
Arnulfo Hernan Nava-Zavala
One of the main groups of lipids is phospholipids, which are mainly involved in forming cell membranes. Neoplastic processes such as cell replication have increased lipid synthesis, making tumor cells dependent on this synthesis to maintain their requirements. Antiphospholipid antibodies attack phospholipids in the cell membranes. Three main types of antiphospholipid antibodies are recognized: anti-β2 glycoprotein I (anti-β2GP-I), anticardiolipin (aCL), and lupus anticoagulant (LA). These types of antibodies have been proven to be present in hematological neoplasms, particularly in LH and NHL. This review on antiphospholipid antibodies in hematological neoplasms describes their clinical relationship as future implications at the prognostic level for survival and even treatment.

6 August 2023 in Healthcare
Verified
Journal Article
Open access
PDF file
SBSonia Guadalupe Barreno-Rocha
Sonia Guadalupe Barreno-Rocha
SGSandra Guzmán-Silahua
Sandra Guzmán-Silahua
EMErnesto German GERMAN Cardona Muñoz
Ernesto German GERMAN Cardona Muñoz
MZMaria G Zavala-Cerna
Maria G Zavala-Cerna
DGDavid Eduardo Muñoz Gaytan
David Eduardo Muñoz Gaytan
ANArnulfo Hernan Nava-Zavala
Arnulfo Hernan Nava-Zavala
(1) Background: Non-Hodgkin Lymphoma is a neoplasm that can significantly compromise the immune system, but timely assessment can change the patient outcome. In cancer, the activation of the immune system could lead to the secretion of autoantibodies. (2) Methods: A retrospective cohort study was performed from 2017 to 2019 in patients with Non-Hodgkin Lymphoma diagnosed with a biopsy. (3) Results: We included 39 patients who were newly diagnosed, untreated, and without any autoimmune disease previously reported. Thirty patients had the presence of autoantibodies (antiphospholipid antibodies, anti-cytoplasmic neutrophils antibodies, antinuclear antibodies), and nine were without autoantibodies. There were no statistical differences among groups regarding clinical, demographic, staging, and prognosis characteristics. Also, there were no differences in the outcomes of the patients after finishing chemotherapy and one year after initiating treatment. (4) Conclusions: Further investigations must be conducted regarding an extended panel of autoantibodies because the panel of autoantibodies in this study did not show a relationship between the presence and the clinical outcome of the patients.